



(omalizumab) for subcutaneous use

SAMPLE CODING

Chronic Spontaneous Urticaria

| ТҮРЕ | CODE | | DESCRIPTION | | |
|--|--------------|---------------|--|--------------------------|--|
| Diagnosis: ICD-10-CM | L50.0 | | Allergic urticaria | | |
| | L50.1 | | Idiopathic urticaria | | |
| | L50.8 | | Other (chronic, recurrent) urticaria | | |
| | L50.9 | | Urticaria, unspecified | | |
| Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. | 10-digit | 11-digit | | | |
| | 50242-214-01 | 50242-0214-01 | Previous 75-mg Prefilled Syringe | d Syringe | |
| | 50242-215-01 | 50242-0215-01 | Previous 150-mg Prefilled Syringe | .50-mg Prefilled Syringe | |
| | 50242-214-03 | 50242-0214-03 | Updated 75-mg Prefilled Syringe | NDCs are effective | |
| | 50242-215-03 | 50242-0215-03 | Updated 150-mg Prefilled Syringe | April 11, 2025. | |
| | 50242-040-62 | 50242-0040-62 | 150-mg Single-dose Vial | | |
| | 50242-227-01 | 50242-0227-01 | 300-mg Prefilled Syringe | | |
| | 50242-214-55 | 50242-0214-55 | 75-mg Autoinjector | | |
| | 50242-215-55 | 50242-0215-55 | 150-mg Autoinjector | | |
| | 50242-227-55 | 50242-0227-55 | 300-mg Autoinjector | | |
| Drug: HCPCS | J2357 | | Injection, omalizumab, 5 mg* | | |
| HCPCS: Modifier [†] | JZ | | Zero drug amount discarded/not administered to any patient | | |
| Administration procedures: CPT | 96372 | | Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | | |

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech and Novartis do not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for Important Safety Information.

^{*}Applies to all NDC codes for XOLAIR.

[†]The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.